139 related articles for article (PubMed ID: 15061198)
1. Prognostic significance of surface markers expressed in multiple myeloma: CD56 and other antigens.
Sahara N; Takeshita A
Leuk Lymphoma; 2004 Jan; 45(1):61-5. PubMed ID: 15061198
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma.
Sahara N; Takeshita A; Shigeno K; Fujisawa S; Takeshita K; Naito K; Ihara M; Ono T; Tamashima S; Nara K; Ohnishi K; Ohno R
Br J Haematol; 2002 Jun; 117(4):882-5. PubMed ID: 12060125
[TBL] [Abstract][Full Text] [Related]
3. Expression of cytoadhesion molecules (CD56, CD54, CD18 and CD29) by myeloma plasma cells.
Van Riet I; De Waele M; Remels L; Lacor P; Schots R; Van Camp B
Br J Haematol; 1991 Nov; 79(3):421-7. PubMed ID: 1721526
[TBL] [Abstract][Full Text] [Related]
4. CD56 expression in multiple myeloma: Correlation with poor prognostic markers but no effect on outcome.
Koumpis E; Tassi I; Malea T; Papathanasiou K; Papakonstantinou I; Serpanou A; Tsolas E; Kapsali E; Vassilakopoulos TP; Papoudou-Bai A; Hatzimichael E
Pathol Res Pract; 2021 Sep; 225():153567. PubMed ID: 34352440
[TBL] [Abstract][Full Text] [Related]
5. CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction.
Skerget M; Skopec B; Zadnik V; Zontar D; Podgornik H; Rebersek K; Furlan T; Cernelc P
Acta Haematol; 2018; 139(4):228-234. PubMed ID: 29920491
[TBL] [Abstract][Full Text] [Related]
6. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
Martín P; Santón A; Bellas C
Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Relevance of Concordant Expression CD69 and CD56 in Response to Bortezomib Combination Therapy in Multiple Myeloma Patients.
ElMenshawy N; Farag NA; Atia DM; Abousamra N; Shahin D; Fawzi E; Ghazi H; El-Kott AF; Eissa M
Cancer Invest; 2021 Oct; 39(9):777-782. PubMed ID: 34344244
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical evaluation of 95 bone marrow reactive plasmacytoses.
Ioannou MG; Stathakis E; Lazaris AC; Papathomas T; Tsiambas E; Koukoulis GK
Pathol Oncol Res; 2009 Mar; 15(1):25-9. PubMed ID: 18553158
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological correlates of CD56 expression in multiple myeloma: a unique entity?
Mathew P; Ahmann GJ; Witzig TE; Roche PC; Kyle RA; Greipp PR
Br J Haematol; 1995 Jun; 90(2):459-61. PubMed ID: 7540857
[TBL] [Abstract][Full Text] [Related]
10. The neural cell adhesion molecule NCAM in multiple myeloma.
Kaiser U; Auerbach B; Oldenburg M
Leuk Lymphoma; 1996 Feb; 20(5-6):389-95. PubMed ID: 8833394
[TBL] [Abstract][Full Text] [Related]
11. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma.
Pellat-Deceunynck C; Barillé S; Jego G; Puthier D; Robillard N; Pineau D; Rapp MJ; Harousseau JL; Amiot M; Bataille R
Leukemia; 1998 Dec; 12(12):1977-82. PubMed ID: 9844928
[TBL] [Abstract][Full Text] [Related]
12. Soluble and membrane levels of molecules involved in the interaction between clonal plasma cells and the immunological microenvironment in multiple myeloma and their association with the characteristics of the disease.
Perez-Andres M; Almeida J; Martin-Ayuso M; De Las Heras N; Moro MJ; Martin-Nuñez G; Galende J; Cuello R; Abuín I; Moreno I; Domínguez M; Hernandez J; Mateo G; San Miguel JF; Orfao A
Int J Cancer; 2009 Jan; 124(2):367-75. PubMed ID: 19003959
[TBL] [Abstract][Full Text] [Related]
13. Soluble CD56 (NCAM): a new differential-diagnostic and prognostic marker in multiple myeloma.
Kaiser U; Oldenburg M; Jaques G; Auerbach B; Havemann K
Ann Hematol; 1996 Sep; 73(3):121-6. PubMed ID: 8841099
[TBL] [Abstract][Full Text] [Related]
14. Differential gene expression of the neural cell adhesion molecule (N-CAM) in a panel of multiple myeloma cell lines.
De Greef C; Van Riet I; Bakkus MH; Van Camp B
Leukemia; 1998 Jan; 12(1):86-93. PubMed ID: 9436925
[TBL] [Abstract][Full Text] [Related]
15. Massive central nervous system infiltration by CD56-positive plasma cells in multiple myeloma.
Lopes AC; Xavier FD; de Souza Barroso R; Gomes HR; Sales MM
Cytopathology; 2017 Apr; 28(2):172-174. PubMed ID: 27489145
[No Abstract] [Full Text] [Related]
16. Prognostic impact of CD200 and CD56 expression in adult acute lymphoblastic leukemia patients.
Aref S; Azmy E; El-Bakry K; Ibrahim L; Mabed M
Hematology; 2018 Jun; 23(5):263-270. PubMed ID: 29161980
[TBL] [Abstract][Full Text] [Related]
17. Immunophenotypic characteristics and clinical relevance of CD56+ and CD56- extranodal nasal-type natural killer/T-cell lymphoma.
Li YX; Wang H; Feng XL; Liu QF; Wang WH; Lv N; Jin J; Wang SL; Liu YP; Fang H; Song YW; Liu XF; Zhou LQ; Wang ZY; Yu ZH
Leuk Lymphoma; 2011 Mar; 52(3):417-24. PubMed ID: 21323521
[TBL] [Abstract][Full Text] [Related]
18. Association between intracranial plasmacytoma and multiple myeloma: clinicopathological outcome study.
Schwartz TH; Rhiew R; Isaacson SR; Orazi A; Bruce JN
Neurosurgery; 2001 Nov; 49(5):1039-44; discussion 1044-5. PubMed ID: 11846895
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the CD56 promoter and its association with proliferation, anti-apoptosis and clinical factors in multiple myeloma.
Damgaard T; Knudsen LM; Dahl IM; Gimsing P; Lodahl M; Rasmussen T
Leuk Lymphoma; 2009 Feb; 50(2):236-46. PubMed ID: 19235015
[TBL] [Abstract][Full Text] [Related]
20. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression.
Rawstron A; Barrans S; Blythe D; Davies F; English A; Pratt G; Child A; Morgan G; Jack A
Br J Haematol; 1999 Jan; 104(1):138-43. PubMed ID: 10027726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
